ArticleFrontiers in endocrinology2025
Prospective analysis of metabolic syndrome and inflammation in aortic aneurysm risk: UK Biobank study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context/Objectives: Metabolic syndrome (MetS) is associated with various diseases, yet its connection with aortic aneurysm (AA) is not well understood. The role of chronic inflammation as a mediator in this relationship also remains unclear. This study explores the combined effects of MetS and inflammation on AA risk. Methods: Data from 312,505 UK Biobank participants were analyzed to assess the relationship between MetS and AA. Cox proportional hazards regression models evaluated the association, while restricted cubic splines, mediation analyses, interaction assessments, and joint analyses explored the impact of inflammatory indicators, including the low-grade chronic inflammation (INFLA) score. Results: Over a mean follow-up of 14.6 years, 2,382 participants developed AA. MetS was associated with a higher AA risk (HR: 1.27; 95% CI: 1.16-1.39) in fully adjusted models. Each additional MetS component increased AA risk by 16%. Inflammatory markers, including the INFLA score, significantly mediated this relationship. Joint analyses revealed a stronger association in MetS patients with high INFLA scores (HR: 1.68; 95% CI: 1.45-1.95). Conclusion: MetS and its components notably elevate AA risk, with inflammation playing a key mediating role. These findings underscore the importance of targeted prevention strategies, particularly for MetS populations with high chronic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.